NattoPharma ASA: Compagnie des Levures Lesaffre announces completion of compulsory acquisition

Lille/Oslo, 9 June 2021

Reference is made to the stock exchange announcement earlier today, 9 June 2021, regarding  Compagnie des Levures Lesaffre's ("Lesaffre") announcement of a compulsory acquisition of all shares in NattoPharma ASA ("NattoPharma" or the "Company") not already owned by Lesaffre.

The Board of Directors of Lesaffre has, effective from close of trading on Oslo Børs today, 9 June 2021, resolved to carry out the compulsory acquisition of all remaining shares in NattoPharma not owned by Lesaffre, pursuant to the Norwegian Public Limited Liability Companies Act section 4-25 cf. the Norwegian Securities Trading Act section 6-22 (1). As a consequence, Lesaffre has assumed ownership of all shares in the Company.

The offered redemption price under the compulsory acquisition is NOK 35.00 per share, which corresponds to the offer price in the preceding mandatory offer and, according to the Norwegian Securities Trading Act section 6-22 (2), is the applicable redemption price in a subsequent compulsory acquisition. Lesaffre has deposited the total acquisition amount on a separate account with Nordea, in accordance with the Norwegian Public Limited Liability Companies Act section 4-25 (5).

A notice regarding the compulsory acquisition will be sent to all former shareholders subject to the compulsory transfer, whose addresses are known. In addition, the compulsory acquisition will be announced through the electronic notice service of the Norwegian Register of Business Enterprises (Nw. Brønnøysundregistrene) if required pursuant to applicable law.

As a consequence of the compulsory acquisition, Lesaffre will pursue a de-listing of the Company's shares from Euronext Expand. Separate stock exchange notices will be published regarding the timing for such delisting.

Oslo Børs is requested to suspend the Company's shares from trading without delay.

Rothschild is acting as financial adviser to Lesaffre and Nordea Bank Abp, filial i Norge, is acting as receiving agent. Advokatfirmaet Thommessen AS is acting as the Norwegian legal adviser, and Linklaters is acting as the French legal adviser, to Lesaffre.

For further information, please contact:

NattoPharma:

NattoPharma ASA
Att: Kjetil Ramsøy
Telephone: +47 906 12 943
Email: kjetil.ramsoy@nattopharma.com

Lesaffre:

Agence Wellcom
Att: Valérie Lassale/Chloe Bencivengo
Telephone: +33(0)1 46 34 60 60
Email: lesaffre@wellcom.fr